Mahendra G Dedhiya

This inventor holds 24 USPTO granted patents and 54 published patent applications, plus 5 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Forest Laboratories Holdings Limited, Richter Gedeon Nyrt., Ironwood Pharmaceuticals, Inc.. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mahendra G Dedhiya. Retrieved from https://idiyas.com/inventor/mahendra-g-dedhiya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 54)

% Patents Active = 95.8

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 13 (Patent Applications = 12)

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 188(Granted Patents)

Company Filing History:

9 out of 26

Forest Laboratories Holdings Limited

Ironwood Pharmaceuticals, Inc.

patents

4. 8 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...

Areas of Expertise:

Dopamine Receptor Ligands

Linaclotide

Heterocyclic Compounds

Crystalline Forms

Modified Release

Oral Dosage Forms

GC-C Receptor Agonist

Cephem Compounds

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE49302 - Pharmaceutical formulations containing dopamine receptor ligands (2022-11-14),

2. RE49110 - Pharmaceutical formulations containing dopamine receptor ligands (2022-06-20),

3. 10702576 - Stable formulations of linaclotide (2020-07-07),

4. 10675325 - Stable formulations of linaclotide (2020-06-09),

5. 10660868 - Modified release formulations of memantine oral dosage forms (2020-05-26),

6. RE47350 - Pharmaceutical formulations containing dopamine receptor ligands (2019-04-15),

7. RE47333 - Pharmaceutical formulations containing dopamine receptor ligands (2019-04-01),

8. 9695122 - Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (2017-07-04),

9. 9580424 - Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt (2017-02-28),

10. 9284314 - Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (2016-03-15),

11. 9259403 - Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide (2016-02-16),

12. 9062053 - Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt (2015-06-23),

13. 9056846 - Pharmaceutical formulations containing dopamine receptor ligands (2015-06-16),

14. 9056845 - Pharmaceutical formulations containing dopamine receptor ligands (2015-06-16),

15. 8969566 - Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (2015-03-03),

Title: Mahendra G Dedhiya: Pioneering Inventor from Pomona, NY

Introduction: Mahendra G Dedhiya is a highly accomplished inventor based in Pomona, NY, known for his groundbreaking innovations in various fields.

Latest Patents: Mahendra G Dedhiya holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Mahendra G Dedhiya has consistently pushed the boundaries of innovation, earning recognition for his forward-thinking solutions and cutting-edge inventions.

Collaborations: Throughout his career, Mahendra G Dedhiya has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Mahendra G Dedhiya's passion for innovation and his relentless drive to create have solidified his reputation as a trailblazing inventor, inspiring the next generation of innovators to think boldly and push the limits of what is possible.

Profile summary based on public USPTO records.